Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn’s Disease: Patient Selection and Reported Outcomes

Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn’s Disease: Patient Selection and Reported Outcomes

Sara Horst,1 Raymond K Cross2 1Vanderbilt University Medical Center, Nashville, TN, USA; 2University of Maryland School of Medicine, Baltimore, MD, USACorrespondence: Sara Horst, Vanderbilt University Medical Center, Inflammatory Bowel Disease Clinic, 719 Thompson Lane, Suite, 20500, Nashville, TN,...

Full description

Bibliographic Details
Main Authors: Horst S, Cross RK
Format: Article
Language:English
Published: Dove Medical Press 2023-01-01
Series:Drug Design, Development and Therapy
Subjects:
crohn’s disease
risankizumab
biological therapy
interleukin-23 subunit p19
remission induction
Online Access:https://www.dovepress.com/clinical-evaluation-of-risankizumab-in-the-treatment-of-adults-with-mo-peer-reviewed-fulltext-article-DDDT

Internet

https://www.dovepress.com/clinical-evaluation-of-risankizumab-in-the-treatment-of-adults-with-mo-peer-reviewed-fulltext-article-DDDT

Similar Items